Daniel P. Fitzgerald

Daniel P. Fitzgerald

Auto-generated profile, based on publicly available information

Daniel P. Fitzgerald

NextCure Inc., Beltsville, MD 20705, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in Science Advances
Verified
Journal Article
Open access
KPKushal Prajapati
Kushal Prajapati
CYChuan Yan
Chuan Yan
QYQiqi Yang
Qiqi Yang
SASteven Arbitman
Steven Arbitman
DFDaniel P. Fitzgerald
Daniel P. Fitzgerald
DFDallas B. Flies
Dallas B. Flies
Cancers exploit coinhibitory receptors on T cells to escape tumor immunity, and targeting such mechanisms has shown remarkable clinical benefit, but in a limited subset of patients. We hypothesized that cancer cells mimic noncanonical mechanisms of early development such as axon guidance pathways to evade T cell immunity. Using gain-of-function genetic screens, we profiled axon guidance proteins on human T cells and their cognate ligands and identified fibronectin leucine-rich transmembrane protein 3 (FLRT3) as a ligand that inhibits T cell activity. We demonstrated that FLRT3 inhibits T cells through UNC5B, an axon guidance receptor that is up-regulated on activated human T cells. FLRT3 expressed in human cancers favored tumor growth and inhibited CAR-T and BiTE + T cell killing and infiltration in humanized cancer models. An FLRT3 monoclonal antibody that blocked FLRT3-UNC5B interactions reversed these effects in an immune-dependent manner. This study supports the concept that axon guidance proteins mimic T cell checkpoints and can be targeted for cancer immunotherapy.